File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: A meta-analysis on intravenous magnesium sulphate for treating acute asthma
  • Basic View
  • Metadata View
  • XML View
TitleA meta-analysis on intravenous magnesium sulphate for treating acute asthma
 
AuthorsCheuk, DKL1
Chau, TCH2
Lee, SL1
 
Issue Date2005
 
PublisherB M J Publishing Group. The Journal's web site is located at http://www.archdischild.com/
 
CitationArchives of Disease in Childhood, 2005, v. 90 n. 1, p. 74-77 [How to Cite?]
DOI: http://dx.doi.org/10.1136/adc.2004.050005
 
AbstractAIM: To evaluate the effectiveness of intravenous magnesium sulphate in the treatment of acute asthmatic attacks in children by meta-analysis. METHODS: A systematic and comprehensive search of the literature was performed to identify controlled clinical trials of magnesium sulphate in paediatric acute asthma which evaluated outcomes of hospitalisation or short term pulmonary function tests or symptom scores. Unpublished data were searched by personal contacts with authors and specialists. Two reviewers independently assessed trial qualities and synthesised data. Heterogeneity among studies was evaluated by the Cochrane Q test. Outcome data were pooled by random or fixed effect models depending on presence or absence of heterogeneity. RESULTS: Five randomised placebo controlled trials involving a total of 182 patients were identified. They compared intravenous magnesium sulphate to placebo in treating paediatric patients with moderate to severe asthmatic attacks in the emergency department, with co-therapies of inhaled beta2 agonists and systemic steroids. The studies were of high quality with results judged to be valid. Four studies showed that magnesium sulphate was effective, while one study found it ineffective. There was no significant heterogeneity in the primary outcome of hospitalisation. In the fixed effect model, magnesium sulphate is effective in preventing hospitalisation (OR 0.290, 95% CI 0.143 to 0.589). The number needed to treat is 4 (95% CI 3 to 8). Secondary outcomes of short term pulmonary function tests and clinical symptom scores also showed significant improvement. CONCLUSION: Intravenous magnesium sulphate probably provides additional benefit in moderate to severe acute asthma in children treated with bronchodilators and steroids.
 
ISSN0003-9888
2013 Impact Factor: 2.905
 
DOIhttp://dx.doi.org/10.1136/adc.2004.050005
 
PubMed Central IDPMC1720072
 
ISI Accession Number IDWOS:000225865900019
 
DC FieldValue
dc.contributor.authorCheuk, DKL
 
dc.contributor.authorChau, TCH
 
dc.contributor.authorLee, SL
 
dc.date.accessioned2007-10-30T06:19:56Z
 
dc.date.available2007-10-30T06:19:56Z
 
dc.date.issued2005
 
dc.description.abstractAIM: To evaluate the effectiveness of intravenous magnesium sulphate in the treatment of acute asthmatic attacks in children by meta-analysis. METHODS: A systematic and comprehensive search of the literature was performed to identify controlled clinical trials of magnesium sulphate in paediatric acute asthma which evaluated outcomes of hospitalisation or short term pulmonary function tests or symptom scores. Unpublished data were searched by personal contacts with authors and specialists. Two reviewers independently assessed trial qualities and synthesised data. Heterogeneity among studies was evaluated by the Cochrane Q test. Outcome data were pooled by random or fixed effect models depending on presence or absence of heterogeneity. RESULTS: Five randomised placebo controlled trials involving a total of 182 patients were identified. They compared intravenous magnesium sulphate to placebo in treating paediatric patients with moderate to severe asthmatic attacks in the emergency department, with co-therapies of inhaled beta2 agonists and systemic steroids. The studies were of high quality with results judged to be valid. Four studies showed that magnesium sulphate was effective, while one study found it ineffective. There was no significant heterogeneity in the primary outcome of hospitalisation. In the fixed effect model, magnesium sulphate is effective in preventing hospitalisation (OR 0.290, 95% CI 0.143 to 0.589). The number needed to treat is 4 (95% CI 3 to 8). Secondary outcomes of short term pulmonary function tests and clinical symptom scores also showed significant improvement. CONCLUSION: Intravenous magnesium sulphate probably provides additional benefit in moderate to severe acute asthma in children treated with bronchodilators and steroids.
 
dc.description.naturepublished_or_final_version
 
dc.format.extent166274 bytes
 
dc.format.extent1778 bytes
 
dc.format.mimetypeapplication/pdf
 
dc.format.mimetypetext/plain
 
dc.identifier.citationArchives of Disease in Childhood, 2005, v. 90 n. 1, p. 74-77 [How to Cite?]
DOI: http://dx.doi.org/10.1136/adc.2004.050005
 
dc.identifier.citeulike3401720
 
dc.identifier.doihttp://dx.doi.org/10.1136/adc.2004.050005
 
dc.identifier.isiWOS:000225865900019
 
dc.identifier.issn0003-9888
2013 Impact Factor: 2.905
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC1720072
 
dc.identifier.pmid15613519
 
dc.identifier.scopuseid_2-s2.0-11144229833
 
dc.identifier.urihttp://hdl.handle.net/10722/45209
 
dc.languageeng
 
dc.publisherB M J Publishing Group. The Journal's web site is located at http://www.archdischild.com/
 
dc.rightsArchives of Disease in Childhood. Copyright © B M J Publishing Group.
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshAnti-Asthmatic-Agents-administration-and-dosage
 
dc.subject.meshAsthma-drug-therapy
 
dc.subject.meshMagnesium-Sulfate-administration-and-dosage
 
dc.titleA meta-analysis on intravenous magnesium sulphate for treating acute asthma
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cheuk, DKL</contributor.author>
<contributor.author>Chau, TCH</contributor.author>
<contributor.author>Lee, SL</contributor.author>
<date.accessioned>2007-10-30T06:19:56Z</date.accessioned>
<date.available>2007-10-30T06:19:56Z</date.available>
<date.issued>2005</date.issued>
<identifier.citation>Archives of Disease in Childhood, 2005, v. 90 n. 1, p. 74-77</identifier.citation>
<identifier.issn>0003-9888</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/45209</identifier.uri>
<description.abstract>AIM: To evaluate the effectiveness of intravenous magnesium sulphate in the treatment of acute asthmatic attacks in children by meta-analysis. METHODS: A systematic and comprehensive search of the literature was performed to identify controlled clinical trials of magnesium sulphate in paediatric acute asthma which evaluated outcomes of hospitalisation or short term pulmonary function tests or symptom scores. Unpublished data were searched by personal contacts with authors and specialists. Two reviewers independently assessed trial qualities and synthesised data. Heterogeneity among studies was evaluated by the Cochrane Q test. Outcome data were pooled by random or fixed effect models depending on presence or absence of heterogeneity. RESULTS: Five randomised placebo controlled trials involving a total of 182 patients were identified. They compared intravenous magnesium sulphate to placebo in treating paediatric patients with moderate to severe asthmatic attacks in the emergency department, with co-therapies of inhaled beta2 agonists and systemic steroids. The studies were of high quality with results judged to be valid. Four studies showed that magnesium sulphate was effective, while one study found it ineffective. There was no significant heterogeneity in the primary outcome of hospitalisation. In the fixed effect model, magnesium sulphate is effective in preventing hospitalisation (OR 0.290, 95% CI 0.143 to 0.589). The number needed to treat is 4 (95% CI 3 to 8). Secondary outcomes of short term pulmonary function tests and clinical symptom scores also showed significant improvement. CONCLUSION: Intravenous magnesium sulphate probably provides additional benefit in moderate to severe acute asthma in children treated with bronchodilators and steroids.</description.abstract>
<format.extent>166274 bytes</format.extent>
<format.extent>1778 bytes</format.extent>
<format.mimetype>application/pdf</format.mimetype>
<format.mimetype>text/plain</format.mimetype>
<language>eng</language>
<publisher>B M J Publishing Group. The Journal&apos;s web site is located at http://www.archdischild.com/</publisher>
<rights>Archives of Disease in Childhood. Copyright &#169; B M J Publishing Group.</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Anti-Asthmatic-Agents-administration-and-dosage</subject.mesh>
<subject.mesh>Asthma-drug-therapy</subject.mesh>
<subject.mesh>Magnesium-Sulfate-administration-and-dosage</subject.mesh>
<title>A meta-analysis on intravenous magnesium sulphate for treating acute asthma</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0003-9888&amp;volume=90&amp;issue=1&amp;spage=74&amp;epage=77&amp;date=2005&amp;atitle=A+meta-analysis+on+intravenous+magnesium+sulphate+for+treating+acute+asthma</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1136/adc.2004.050005</identifier.doi>
<identifier.pmid>15613519</identifier.pmid>
<identifier.pmcid>PMC1720072</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-11144229833</identifier.scopus>
<identifier.isi>WOS:000225865900019</identifier.isi>
<identifier.citeulike>3401720</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/45209/1/121237.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Hong Kong Baptist University